{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:37:19Z","timestamp":1793637439852,"version":"4.5.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The standard of care for pediatric growth hormone deficiency (pGHD) is once-daily recombinant human growth hormone (rhGH). Somatrogon, a long-acting rhGH, requires less frequent, once-weekly, dosing. We describe physicians\u2019 preference for, experiences, and satisfaction with once-weekly somatrogon vs once-daily rhGH.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>English-speaking investigators from somatrogon\u2019s global phase III study (NCT02968004) with prior experience using once-daily rhGH were included. Participants answered an online survey containing 14 closed- and open-ended items.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-four pediatric endocrinologists (41.7% men; 79.2% practiced at public\/private hospitals) from 12 countries with 25.8 \u00b1 12.0 years\u2019 experience treating pGHD completed the survey. In terms of the time and effort required to explain device instructions, injection regimen, procedure for missed injection, and address patients\u2019\/caregivers\u2019 concerns, a similar proportion of physicians chose once-weekly somatrogon and once-daily rhGH; 62.5% physicians indicated that once-daily rhGH required greater effort to monitor adherence. Overall, 75% preferred once-weekly somatrogon over once-daily rhGH, 79.2% considered once-weekly somatrogon to be more convenient and less burdensome, and 83.3% were likely to prescribe somatrogon in the future. Overall, 50% felt that once-weekly somatrogon was more beneficial to patients, while 50% chose \u201cNo difference\u201d. Most physicians (62.5%) felt both regimens were equally likely to support positive long-term growth outcomes and reduce healthcare utilization. More physicians were \u201cvery satisfied\u201d with once-weekly somatrogon (62.5%) than with once-daily rhGH (16.7%). Reduced injection frequency, patient and caregiver burden, increased convenience, and improved adherence were reasons for these choices.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Physicians had a positive experience with, and perception of, treating pGHD with once-weekly somatrogon.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1254424","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T05:13:01Z","timestamp":1698297181000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Physician experience with once-weekly somatrogon versus once-daily rhGH regimen in pediatric patients with growth hormone deficiency: a cross-sectional survey of physicians from the global phase 3 study"],"prefix":"10.3389","volume":"14","author":[{"given":"Roy","family":"Gomez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Lamoureux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane M.","family":"Turner-Bowker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Maghnie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley S.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Polak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Yaworsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/pch\/18.10.533","article-title":"Quality of referral of short children to the paediatric endocrinologist and impact of a fax communication system.Paediatr","volume":"18","author":"Chiniara","year":"2013","journal-title":"Child Health"},{"key":"B2","unstructured":"CalabriaA\n          Growth hormone deficiency in children (pituitary dwarfism)2022"},{"key":"B3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/MED.0b013e32834ec952","article-title":"Diagnosis of growth hormone deficiency in childhood","volume":"19","author":"Stanley","year":"2012","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/s0022-3476(94)70117-2","article-title":"Utah Growth Study: growth standards and the prevalence of growth hormone deficiency","volume":"125","author":"Lindsay","year":"1994","journal-title":"J Pediatr"},{"key":"B5","article-title":"Prevalence of growth hormone deficiency of children in Beijing","volume":"105","author":"Bao","year":"1992","journal-title":"Chin Med J (Engl)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.117234","article-title":"Evaluation of left ventricular mass and function, lipid profile, and insulin resistance in Egyptian children with growth hormone deficiency: a single-center prospective case-control study","volume":"17","author":"Metwalley","year":"2013","journal-title":"Indian J Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12393","article-title":"Cluster of cardiometabolic risk factors in children with GH deficiency: a prospective, case-control study","volume":"80","author":"Capalbo","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1046\/j.1365-2265.2001.01298.x","article-title":"Increased insulin sensitivity in young, growth hormone deficient children","volume":"55","author":"Husbands","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1159\/000444143","article-title":"Growth hormone deficiency in prepubertal children: predictive markers of cardiovascular disease","volume":"85","author":"De Leonibus","year":"2016","journal-title":"Horm Res Paediatr"},{"key":"B10","unstructured":"BambaV\n          Pediatric growth hormone deficiency2018"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1159\/000452150","article-title":"Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency","volume":"86","author":"Grimberg","year":"2016","journal-title":"Horm Res Paediatr"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-019-02057-x","article-title":"Growth hormone therapy in children: predictive factors and short-term and long-term response criteria","volume":"66","author":"Pozzobon","year":"2019","journal-title":"Endocrine"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-020-09604-2","article-title":"Growth hormone deficiency and replacement in children","volume":"22","author":"Boguszewski","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.11.6984","article-title":"Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society","volume":"85","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2147\/cpaa.S6525","article-title":"Somatotropin in the treatment of growth hormone deficiency and Turner syndrome in pediatric patients: a review","volume":"2","author":"Reh","year":"2010","journal-title":"Clin Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1159\/000350251","article-title":"Understanding the growth hormone therapy adherence paradigm: a systematic review","volume":"79","author":"Fisher","year":"2013","journal-title":"Horm Res Paediatr"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1982682","article-title":"Suboptimal adherence to daily growth hormone in a US real-world study: an unmet need in the treatment of pediatric growth hormone deficiency.Curr","volume":"37","author":"Loftus","year":"2021","journal-title":"Med Res Opin"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1159\/000523791","article-title":"Long-acting growth hormone preparations and their use in children with growth hormone deficiency","author":"Pampanini","year":"2022","journal-title":"Horm Res Paediatr"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2147\/ppa.S239196","article-title":"Factors driving patient preferences for growth hormone deficiency (GHD) injection regimen and injection device features: a discrete choice experiment","volume":"14","author":"McNamara","year":"2020","journal-title":"Patient Prefer Adherence"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.637209","article-title":"Usefulness and potential pitfalls of long-acting growth hormone analogs","volume":"12","author":"Yuen","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.5b00868","article-title":"In vitro and in vivo characterization of MOD-4023, a long-acting carboxy-terminal peptide (CTP)-modified human growth hormone","volume":"13","author":"Hershkovitz","year":"2016","journal-title":"Mol Pharm"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac220","article-title":"Efficacy and safety of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a phase 3 study","volume":"107","author":"Deal","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4103\/ajm.ajm_46_20","article-title":"Physician' attitudes to growth hormone replacement therapy in adults following pituitary surgery: results of an online survey","volume":"10","author":"Ekhzaimy","year":"2020","journal-title":"Avicenna J Med"},{"key":"B24","first-page":"S122","article-title":"Systematic review of patient experience with a less frequent injection schedule for growth hormone deficiency","volume":"27","author":"Loftus","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"B25","unstructured":"FrieseS\n          ATLAS.ti 9 Windows - user manual2021"},{"key":"B26","volume-title":"Computer Programs For Qualitative Data Analysis: A Software Sourcebook","author":"Weitzman","year":"1995"},{"key":"B27","doi-asserted-by":"crossref","DOI":"10.4135\/9781412983655","volume-title":"Cognitive Interviewing: A Tool For Improving Questionnaire Design","author":"Willis","year":"2005"},{"key":"B28","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40272-021-00478-8","article-title":"Lonapegsomatropin: pediatric first approval","volume":"24","author":"Lamb","year":"2022","journal-title":"Paediatr Drugs"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01663-2","article-title":"Somatrogon: first approval","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/56.1.51","article-title":"Physician attitudes toward human growth hormone products","volume":"56","author":"Nelson","year":"1999","journal-title":"Am J Health Syst Pharm"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013730","article-title":"What drives the prescribing of growth hormone preparations in England? Prices versus patient preferences","volume":"7","author":"Chapman","year":"2017","journal-title":"BMJ Open"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvac117","article-title":"Treatment burden of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a randomized study","volume":"6","author":"Maniatis","year":"2022","journal-title":"J Endocr Soc"},{"key":"B33","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/B978-0-323-29738-7.00008-3","article-title":"Pituitary physiology and diagnostic evaluation","volume-title":"Williams Textbook Of Endocrinology","author":"Kaiser","year":"2016"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/med.0000000000000416","article-title":"The current state of long-acting growth hormone preparations for growth hormone therapy","volume":"25","author":"Yuen","year":"2018","journal-title":"Curr Opin Endocrinol Diabetes Obes"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1254424\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T05:13:08Z","timestamp":1698297188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1254424\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,17]]},"references-count":34,"alternative-id":["10.3389\/fendo.2023.1254424"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1254424","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,17]]},"article-number":"1254424"}}